Performance Overview - The company reported a revenue of 308 million yuan for 2025, representing a year-on-year growth of 65.26%. The net profit reached 15.1578 million yuan, showing a significant increase of 153.62% [1] Company Status - On January 9, 2026, the company announced an employee stock ownership plan draft involving 48 core employees, with a lock-up period of 14 months. The performance assessment targets include a sales volume or net profit growth rate of no less than 12% for 2026. The implementation and its impact on team stability will be worth monitoring [2] Funding Dynamics - The fourth extraordinary general meeting of shareholders approved the bank credit limit for 2026, with the resolution announced on January 6, 2026. Attention should be paid to whether the actual allocation of funds supports business expansion or technological upgrades [3] Business Progress - Following the acquisition of Intricon's hearing health business in 2024, the sales revenue from hearing aid chips reached approximately 20 million yuan in 2025, showing significant year-on-year growth. The demand for OTC hearing aids in the U.S. continues to rise amid global aging trends, and future focus may be on technology integration and omnichannel operations [4]
锦好医疗2026年关注点：年报发布、员工持股计划与业务整合